Peptide Research Database

Access 7,487 peer-reviewed studies, clinical trials, and research papers on peptides. Filter by key research, study type, compound, and category. Direct links to full PubMed entries for comprehensive, evidence-based exploration.

Animal Study
Notable
PMID: 43033890
2026 Nov 14

Effects of N-acetylcysteine administration on anxiety and hedonic-like behaviours, neuroendocrine and redox-related dysfunctions induced by two-hit stress exposure in male and female rats.

In a rat study, our data showed that PNS modulates the vulnerability to a second stress during adolescence, highlighting the pivotal role of early-life fetal programming. Here, we investigated the effects of a long-term administration with the cell-damage-fighting compound N-Acetylcysteine (NAC) on a two-hit stress exposure paradigm in male and female rats, i.e.

Bove M, Sikora V, Dimonte S, Palmieri MA, Cordisco A, Morgese MG, Monteleone M, Caraci F, Campolongo P, Riva MA, Trabace L, Schiavone S

Early life stress may reshape the response to later adverse events. Animal models of prenatal stress (PNS) represent tools to unravel underpinning mechanisms, among which redox imbalance and neuroendocrine dysfunctions play a crucial role. Here, we investigated the effects of a chronic administration with the antioxidant compound N-Acetylcysteine (NAC) on a two-hit stress exposure paradigm in male and female rats, i.e. PNS (by maternal restraint-first hit), combined with social isolation during adolescence (second hit). Hedonic and anxiety-like behaviours were assessed by Sucrose Preference and Elevated Plus Maze (EPM) tests. Plasmatic levels of ROS, malondialdehyde, oxytocin and corticosterone were quantified, together with hypothalamic corticotropin-releasing factor. Moreover, activities of antioxidant enzymes superoxide dismutase (SOD), catalase and glutathione peroxidase (GPx) were also assessed. PNS-exposed males and females exhibited an increased hedonic response, regardless of the second hit. Decreased time spent in the EPM open arms in both PNS-grouped and PNS-isolated males and females was detected, counterbalanced by NAC treatment only in females. CRF and ROS levels were increased in two-hit stress-exposed males and females, with a NAC-induced reduction. Oxytocin content, decreased in females following PNS and PNS-ISO exposure, was restored by NAC in PNS-ISO group. Weaker SOD and CAT activities, together with an enhancement of the GPx, were observed in two-hit exposed males and females, with NAC treatment determining their upregulation. Our data showed that PNS modulates the vulnerability to a second stress during adolescence, highlighting the pivotal role of early-life fetal programming. Furthermore, NAC represents a promising antioxidant compound targeting stress-induced dysfunctions.

Progress in neuro-psychopharmacology & biological psychiatry
Clinical Trial
Landmark Study
PMID: 43033821
2026 Nov 14

Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial.

In a clinical trial, novo Nordisk. Aimed to investigate the efficacy and safety of once per week under the skin cagrilintide-semaglutide 1·7 mg each or 1·0 mg each versus placebo in participants with obesity or overweight and at least one obesity-related complication.

Wharton S, Broholm C, Horn D, Pinta AR, Rubino D, Broholm ZR, Bain SC

Cagrilintide-semaglutide (CagriSema) 2·4 mg each has shown clinically meaningful bodyweight reductions in global phase 3 studies. Different dosing options might support individual treatment responses and tolerability. We aimed to investigate the efficacy and safety of once per week subcutaneous cagrilintide-semaglutide 1·7 mg each or 1·0 mg each versus placebo in participants with obesity or overweight and at least one obesity-related complication. This multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial (REDEFINE 9) was conducted across 24 sites in Canada, France, Germany, the UK, and the USA. Eligible participants were adults aged 18 years or older; with a BMI of at least 30 kg/m2 or at least 27 kg/m2 and one or more obesity-related complication; and without diabetes. Participants were randomly assigned (2:1:2:1) centrally, using block randomisation (block size of six) and a web-based system, to receive cagrilintide 1·7 mg plus semaglutide 1·7 mg (hereafter cagrilintide-semaglutide 1·7 mg each, starting at 0·25 mg each and escalated over 12 weeks), placebo 1·7 mg plus 1·7 mg (hereafter placebo 1·7 mg each), cagrilintide 1·0 mg plus semaglutide 1·0 mg (hereafter cagrilintide-semaglutide 1·0 mg each, starting at 0·25 mg each and escalated over 8 weeks), or placebo 1·0 mg plus 1·0 mg (hereafter placebo 1·0 mg each) for 68 weeks, plus nutrition and physical activity counselling until week 74. All treatments were administered subcutaneously once per week. The coprimary endpoints were relative mean change in bodyweight from baseline to week 68 and proportion of participants reaching a bodyweight reduction of at least 5% at week 68, assessed in the full analysis set (defined as all randomly assigned participants). Safety was assessed in the safety analysis set (defined as all randomly assigned participants who received at least one dose of the study drug). This study is registered with ClinicalTrials.gov, NCT06388187 (completed). From June 24 to Oct 30, 2024, 333 participants were assessed for eligibility and 24 were excluded. 309 participants were randomly assigned (full analysis set: 104 assigned to cagrilintide-semaglutide 1·7 mg each, 103 to cagrilintide-semaglutide 1·0 mg each, and 102 to pooled placebo). 308 participants received at least one dose of the study drug. 291 (94%) of 309 participants completed the study and 254 (82%) were on treatment at week 68. The mean age was 48·0 years (SD 13·6) and mean BMI was 39·1 kg/m2 (6·8). 239 (77%) participants were female, and 70 (23%) were male. For the efficacy estimand, the mean relative change from baseline in bodyweight at week 68 was -20·7% (SE 0·9) with cagrilintide-semaglutide 1·7 mg each, -21·0% (1·0) with cagrilintide-semaglutide 1·0 mg each, and -2·0% (1·0) with the pooled placebo. Bodyweight reductions were significantly greater with both doses of cagrilintide-semaglutide than with placebo (estimated treatment difference [ETD] -18·8 percentage points [95% CI -21·5 to -16·0]; p<0·0001 for the 1·7 mg each dose and -19·0 percentage points [-21·8 to -16·2]; p<0·0001 for the 1·0 mg each dose). The proportion of participants reaching bodyweight reductions of at least 5% at week 68 was significantly greater with cagrilintide-semaglutide than with placebo (95·1% [SE 2·7] with the 1·7 mg each dose vs 33·4% [5·6] with placebo, ETD 61·7 percentage points [95% CI 49·5-74·0], p<0·0001; and 96·3% [2·2] with the 1·0 mg each dose, ETD 63·0 percentage points [51·1-74·9], p<0·0001). Adverse events were reported in 102 (99%) of 103 participants receiving cagrilintide-semaglutide 1·7 mg each, 98 (95%) of 103 receiving cagrilintide-semaglutide 1·0 mg each, and 93 (91%) of 102 receiving the placebo. Most adverse events were mild or moderate and gastrointestinal-related. No deaths were reported. Cagrilintide-semaglutide at 1·7 mg each and 1·0 mg each was superior to placebo at reducing bodyweight in adults with overweight or obesity, suggesting that different dose levels might support treatment flexibility. Novo Nordisk.

The lancet. Diabetes &amp; endocrinology
Other
PMID: 43033301
2026 Nov 14

Tirzepatide and inflammation: a critical reappraisal of the immunometabolic case for incretin-based therapy.

This study found five falsifiable propositions are advanced with the experiments that would refute them.

Jabbar AD

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, lowers high-sensitivity C-reactive protein (hsCRP) by 29-55% across randomised trials in obesity, heart failure with preserved ejection fraction and obstructive sleep apnoea, and interleukin-6 by 25-30% at 72 weeks. Much of this is not weight-mediated: in SURPASS-4 the fall in hsCRP correlated with that in body mass index at r = 0.07, and mediation analysis of trials of semaglutide, a selective GLP-1 receptor agonist, attributes only 21-62% of its hsCRP effect to change in glycated haemoglobin and/or weight. The mechanism, however, is not the one usually given: the account reproduced in most reviews, that incretin receptors on macrophages and T lymphocytes signal through cyclic AMP to restrain nuclear factor-κB, is not supported by the best-controlled data. The principal antibody used to detect the T-cell GLP-1 receptor gives signal in receptor-null cells; Glp1r is undetectable by quantitative PCR in peritoneal and adipose macrophages; and haematopoietic receptor deletion does not abolish semaglutide's anti-atherosclerotic effect. I therefore propose a three-route model, graded by evidence: limited direct signalling in a few validated lymphocyte populations, a central neuro-immune relay, and a large indirect metabolic contribution. That adipose macrophages are refractory to tirzepatide while Kupffer cells respond, and that C-reactive protein is hepatocyte-derived, suggest a substantially hepatic rather than adipose effect. Because the mechanistic evidence concerns GLP-1 receptor agonism almost entirely, the appraisal applies to incretin-based therapy as a class, tirzepatide being the worked example. Five falsifiable propositions are advanced with the experiments that would refute them.

Reviews in endocrine &amp; metabolic disorders
Review
Notable
PMID: 43034163
2026 Nov 14

Systemic and oral adverse effects of semaglutide reported in randomized controlled trials: a scoping review.

In a research review, semaglutide demonstrated an overall favorable safety profile in the included randomized controlled trials, with adverse events predominantly gastrointestinal.

Muknickas D, Câmara JVF, Schestakow A, da Silva Spinola M, Heller D, Hannig M

To map the systemic and oral adverse events (AEs) of semaglutide reported in randomized controlled trials (RCTs). This scoping review was conducted following the PRISMA-ScR guidelines. Only english-language and RCTs were considered. A literature search was conducted in PubMed, Scopus, and Web of Science from 2019 until 2025. Of 630 identified records (300 in PubMed, 312 in Scopus, and 18 in Web of Science), 12 studies were included after screening. The review identified systemic AEs of semaglutide, primarily gastrointestinal events like nausea (12 studies) and diarrhea (11 studies). Less frequent effects included pancreatitis (5 studies), hepatobiliary (3 studies) and gallbladder disease (3 studies), dental caries (1 study) and dry mouth (1 study). Subcutaneous administration predominating (7 studies), followed by oral (3) and mixed routes (2), over treatment durations of 21-68 weeks and 4-9 weeks of follow-up. Additionally, systemic events such as nasopharyngitis (5 studies), COVID-19 (5 studies), and metabolic or nutrition-related disorders were reported in all 12 studies. Importantly, none of the included studies directly investigated oral or dental outcomes. Semaglutide demonstrated an overall favorable safety profile in the included randomized controlled trials, with adverse events predominantly gastrointestinal. However, the RCTs did not provide direct evidence regarding oral health outcomes. Therefore, the available evidence is insufficient to draw conclusions about oral adverse events associated with semaglutide, highlighting the need for randomized clinical trials specifically designed to assess oral health outcomes in patients receiving GLP-1 receptor agonists.

BMC oral health
Animal Study
Notable
DOI
2026-11-13

Single-nucleus RNA-seq atlas of 5xFAD mouse brain maps cell-type-specific transcriptional disruption and preferential rolipram rescue in VIP interneurons

In a mouse study, VIP disinhibitory interneurons emerge as the most transcriptionally vulnerable inhibitory subtype and the preferential site of rolipram-associated rescue, with the Pde7b/CREB1 signaling axis nominating a tractable, disease-context-specific pharmacological substrate.

Potokiri A, Dwamena AA, Wang H.

Background: Alzheimer's disease is characterized by progressive synaptic dysfunction and inhibitory circuit disruption across multiple brain cell types. Rolipram, a selective phosphodiesterase 4 (PDE4) inhibitor that elevates intracellular cyclic AMP (cAMP), activates proteasome, and produces robust procognitive effects in AD mouse models. Still, the cell-type-specific transcriptional mechanisms underlying these effects remain uncharacterized. Methods: We profiled 29,664 nuclei from 5xFAD and wild-type (WT) mouse right hemisphere across four conditions: WT Vehicle, WT Rolipram, 5xFAD Vehicle, and 5xFAD Rolipram (0.03 mg/kg/day, 30-day subcutaneous osmotic pump) using the Parse Biosciences Evercode WT v3 combinatorial barcoding platform. Nuclei were clustered into 16 annotated cell type populations using Seurat v5. Disease and rescue effects were quantified as log fold changes (LFCs) across all clusters, with Gene Ontology enrichment assessed using clusterProfiler and transcription factor activity inferred using decoupleR. Results: Disease-associated transcriptional disruption was highly cell-type-specific in its magnitude. Among inhibitory subtypes, VIP/Reln disinhibitory interneurons (n = 149 nuclei) showed the most coherent transcriptional disruption: 289 candidate genes were lower in 5xFAD, with Gene Ontology enrichment concentrated in synapse organization programs, including regulation of synapse structure or activity (padj = 1.5x10^-14, 44 genes), regulation of synapse organization (padj = 1.9x10^-14, 43 genes), and postsynapse organization (padj = 1.1x10^-13, 38 genes). This pathway-level specificity was not reproduced in PVALB or SST interneurons. Astrocytes showed loss of cell-adhesion programs (cell-substrate adhesion padj = 2.4x10^-4, 10 genes). Rolipram rescue was preferential: VIP interneurons yielded 72 true rescue genes and astrocytes yielded 42, with the remaining 14 clusters showing substantially fewer. The cAMP-specific phosphodiesterase Pde7b was disease-context-specifically lower in 5xFAD VIP interneurons (LFC -0.53) and restored by rolipram (LFC +0.54), with WT expression unchanged. decoupleR CREB1 activity inference identified reduced CREB1 activity in 5xFAD VIP interneurons with partial restoration in 5xFAD Rolipram, supporting a stepwise transcriptional cascade in which amyloid pathology reduces cAMP, which suppresses PKA and CREB1 activity. This in turn reduces Pde7b transcription, and rolipram reverses this cascade by blocking cAMP hydrolysis upstream. Conclusion: This single-nucleus atlas provides the first cell-type-resolved characterization of rolipram's transcriptional effects in the 5xFAD brain. VIP disinhibitory interneurons emerge as the most transcriptionally vulnerable inhibitory subtype and the preferential site of rolipram-associated rescue, with the Pde7b/CREB1 signaling axis nominating a tractable, disease-context-specific pharmacological substrate.

Other
PMID: 43021748
2026 Nov 13

Microdosing, fractional and split dosing of injectable GLP-1-based drugs: balancing potential benefits and risks.

This study found this Special Article aims to provide a critical appraisal of the potential benefits and risks of microdosing, fractional dosing and split dosing of injectable GLP-1-based drugs, which warrant thorough investigation in future how the body processes the drug/pharmacodynamic studies and clinical trials.

Infante M, Seminara G, Fabbri A, Aversa A

Glucagon-like peptide-1 (GLP-1)-based drugs (also known as incretin receptor agonists) have revolutionized the management of type 2 diabetes and overweight/obesity. Microdosing, fractional dosing and split dosing of GLP-1-based drugs administered by subcutaneous injection (particularly the newer incretin receptor agonists semaglutide and tirzepatide) have recently emerged as alternative off-label dosing strategies used to improve long-term treatment tolerability while preserving or optimizing the therapeutic benefits of these agents. Evidence regarding these practices is mostly anecdotal and their use is not supported by manufacturers, scientific societies, drug regulatory agencies and official clinical guidelines. Fractional dosing of injectable incretin receptor agonists is the off-label administration of injectable GLP-1-based drugs at a fraction of a given standard approved drug dose by counting the audible and tactile clicks generated as the dose selector dial of pre-filled multi-dose injection pens (MDPs) is turned forward (off-label "click-counting" method). Microdosing of injectable incretin receptor agonists represents a form of fractional dosing that consists of administering subtherapeutic doses ["microdoses": doses lower than the lowest standard approved drug dose (starting dose)] of injectable GLP-1-based drugs with pre-filled MDPs through the "click-counting" method. Split dosing of injectable once-weekly incretin receptor agonists consists of administering smaller doses of an injectable once-weekly GLP-1-based drug more frequently than once per week with pre-filled MDPs through the "click-counting" method. This Special Article aims to provide a critical appraisal of the potential benefits and risks of microdosing, fractional dosing and split dosing of injectable GLP-1-based drugs, which warrant thorough investigation in future pharmacokinetic/pharmacodynamic studies and clinical trials.

Minerva endocrinology
Case Report
PMID: 43024315
2026 Nov 13

When hypertensive crisis mimics septic shock: A case report of pheochromocytoma-induced severe lactic acidosis following GLP-1 receptor agonist administration.

In a case report, the temporal association with GLP-1 receptor agonist exposure is hypothesis-generating and warrants further investigation as use of these agents continues to expand.

Khan AA, Aslam S, Aqeel M, Agha MA, Khan UA, William M

Pheochromocytoma is a rare catecholamine-secreting tumor that may present atypically with severe lactic acidosis and systemic inflammatory features, closely mimicking sepsis and delaying diagnosis. A possible interaction with glucagon-like peptide-1 (GLP-1) receptor agonists has been suggested but remains poorly understood. A 48-year-old woman with type 2 diabetes mellitus presented with acute nausea, vomiting, chills, severe abdominal pain, and hypertensive crisis within hours of self-administering tirzepatide, a dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonist. She was febrile, tachycardic, and markedly hypertensive, with severe lactic acidosis and systemic inflammatory markers suggestive of sepsis. Initial evaluation favored sepsis; however, negative cultures, sustained severe hypertension, hyperlactatemia disproportionate to perfusion status, and elevated urinary normetanephrines redirected the evaluation toward an endocrine cause. The clinical and biochemical picture supported a diagnosis of probable pheochromocytoma. Imaging revealed a fat-containing left adrenal mass initially suggestive of myelolipoma, representing a diagnostic pitfall. The patient was managed with intravenous fluids, a continuous nicardipine infusion, and oral alpha-blockade with doxazosin. Empiric broad-spectrum antibiotics were started and later discontinued as infection became unlikely. Beta-blockade was withheld until adequate alpha-blockade was achieved. Supportive care and electrolyte correction were provided. Blood pressure and lactate improved over 48 hours with clinical stabilization. The patient was discharged on oral alpha-blockade with plans for outpatient functional imaging (64Cu-DOTATATE positron emission tomography) and definitive surgical evaluation. Pheochromocytoma should be considered in patients presenting with unexplained lactic acidosis and hypertensive crisis, even when sepsis appears likely. Catecholamine-driven type B lactic acidosis can closely mimic infectious shock. Fat-containing adrenal lesions do not exclude pheochromocytoma, and biopsy should be avoided. The temporal association with GLP-1 receptor agonist exposure is hypothesis-generating and warrants further investigation as use of these agents continues to expand.

Meta-Analysis
Highly Cited
DOI
2026-11-13

Evidence availability for 1-year obesity treatment-initiation decisions: an estimand-aligned Bayesian longitudinal network meta-analysis

In a combined analysis of multiple studies, better treatment-policy reporting and randomised evidence on titration and lifestyle support are needed.

Yin X, Dai M, Xia Z, Liu D, Huang G, Li X, Wang X.

Background: Obesity pharmacotherapy strategies differ in maintenance dose, titration, and lifestyle support, but existing syntheses primarily compare drugs rather than treatment-initiation decisions. We assessed 1-year weight reduction, permanent discontinuation, and incremental dose-related trade-offs while mapping the availability of eligible trial evidence. Methods We searched eight databases and two trial registries through October 2026 for randomised trials (at least 12 weeks) of obesity pharmacotherapy initiation in adults with overweight or obesity. Maintenance, withdrawal, and switching trials were excluded. Two reviewers independently selected studies, extracted data, and assessed bias and certainty. Bayesian longitudinal network meta-analysis estimated treatment-policy-compatible weight change at 52 weeks. Additional analyses examined discontinuation, dose escalation, titration, lifestyle support, and diabetes-related attenuation. The study was registered with PROSPERO (CRD420261532130). Findings We included 180 reports from 178 trials (196 randomisation units; 81,014 participants). Only 78 units reached the 1-year evidence layer, 50 informed the primary longitudinal model in adults without diabetes, and 45 of 160 target strategies had non-extrapolated 52-week estimates. Placebo-adjusted weight reductions were greatest with retatrutide 12 mg (-19.80 percentage points, 95% CrI -21.81 to -17.78), tirzepatide 15 mg (-16.87, -18.07 to -15.51), and cagrilintide-semaglutide 2.4/2.4 mg (-16.37, -18.10 to -14.70). Only tirzepatide 15 mg and semaglutide 2.4 mg had high-certainty evidence. Thirteen of 32 strategies increased adverse-event-related permanent discontinuation versus placebo; none increased all-cause discontinuation. Five of 22 adjacent dose steps had at least 0.80 probability of adding more than 2 percentage points of weight reduction. Eight 1-year titration contrasts and three trials of randomised lifestyle-support increments were identified. Weight reduction in adults with type 2 diabetes was 62% of that without diabetes (ratio 0.62, 95% CI 0.58-0.66). Interpretation Evidence directly supporting 1-year obesity treatment-initiation decisions remains limited. Higher-dose and multi-receptor strategies achieve substantial weight reduction, but certainty and discontinuation trade-offs vary. Better treatment-policy reporting and randomised evidence on titration and lifestyle support are needed.

Other
PMID: 43026316
2026 Nov 13

Rare GLP1R variants diminish the weight loss effect of semaglutide but not of tirzepatide.

Nature metabolism
Case Report
Notable
PMID: 43024123
2026 Nov 13

Predictors of early and 6-month remission after transsphenoidal surgery in Cushing's disease: a cohort study of 100 patients.

In a case report, the mean duration of glucocorticoid replacement was 25.55 ± 25.45 months overall; in the 6-month remission group, it was 30.01 ± 25.19 months, reflecting deeper and more prolonged postoperative HPA axis suppression following complete tumor resection. Aimed to identify predictors of early and 6-month remission after TSS in CD patients.

AmirAhmadi M, Abiri B, Mahdavi M, Davoudi Z, Bagheri AK, Rahmani F, Ramezani Ahmadi A, Niroomand M, Hosseinpanah F, Ahmadi N, Grossman A, Valizadeh M

Cushing's disease (CD) is a rare disorder caused by ACTH-secreting pituitary adenomas. Transsphenoidal surgery (TSS) is the first-line treatment, but predictors of remission remain controversial. This study aimed to identify predictors of early and 6-month remission after TSS in CD patients. A cohort study was conducted on 100 patients with confirmed CD who underwent TSS. Biochemical remission was defined using first-week postoperative morning serum cortisol thresholds: < 1.8 µg/dl and < 5 µg/dl for early remission, as well as 6-month remission. Clinical, biochemical, radiological, and postoperative variables were analyzed. Statistical analyses included group comparisons, univariate logistic regression, and ROC curve analysis. Of 100 patients, 58% achieved early remission with cortisol < 1.8 µg/dl, 80% with cortisol < 5 µg/dl, and 84% achieved 6-month remission. Univariate logistic regression identified residual tumor on postoperative MRI (OR = 0.01-0.14, all P < .01) and higher first-week postoperative ACTH level (OR = 0.92-0.93, P < .001) as the most consistent negative correlates of remission across all remission definitions. Macroadenoma was associated with lower odds of 6-month remission (OR = 0.26, P = .019). Higher first-week postoperative cortisol level significantly reduced the likelihood of 6-month remission (OR = 0.69, P < .001). Most preoperative clinical and biochemical parameters, including age, sex, disease duration, BMI, preoperative cortisol and ACTH levels, ODST, LDDST, HDDST, and BIPSS, showed limited or no predictive value (AUC < 0.70, all P > .05). The mean duration of glucocorticoid replacement was 25.55 ± 25.45 months overall; in the 6-month remission group, it was 30.01 ± 25.19 months, reflecting deeper and more prolonged postoperative HPA axis suppression following complete tumor resection. Postoperative first-week cortisol and ACTH levels, tumor size, and residual tumor are significant predictors of remission after TSS, while preoperative parameters do not reliably predict surgical outcomes. Further studies with multivariable analysis are warranted to confirm these findings.